

## DAFTAR PUSTAKA

- Akaa, P., Ahachi, N.C., Vhritherhire, A.R., Agada, E., Jenrola, A.A. and Dzuachii, D., 2017. Five year retrospective study on keloid management. *Journal of Advances in Medicine and Medical Research*, 23(1), pp.1-8.
- Ashok, S. and Ashok, K.P., 2023. Morphometric Analysis of Collagen in Different Grades of Oral Squamous Cell Carcinoma Using Picrosirius Red Stain and Spectrophotometry. *Journal of Microscopy and Ultrastructure*, 11(1), pp.47-51.
- Berman, B., Maderal, A. and Raphael, B., 2017. Keloids and hypertrophic scars: Pathophysiology, classification, and treatment. *Dermatologic Surgery*, 43(1), pp.S3-S18.
- Betarbet, U. and Blalock, T.W., 2020. Keloids: A review of etiology, prevention, and treatment. *The Journal of Clinical and Aesthetic Dermatology*, 13(2), p.33.
- Carroll, L.A., Hanasono, M.M., Mikulec, A.A., Kita, M. and Koch, R.J., 2002. Triamcinolone stimulates bFGF production and inhibits TGF- $\beta$ 1 production by human dermal fibroblasts. *Dermatologic Surgery*, 28(8), pp.704-709.
- Chen, L., Su, Y., Yin, B., Li, S., Cheng, X., He, Y. and Jia, C., 2022. LARP6 regulates keloid fibroblast proliferation, invasion, and ability to synthesize collagen. *Journal of Investigative Dermatology*, 142(9), pp.2395-2405.
- Elsaie, M.L., 2021. Update on management of keloid and hypertrophic scars: A systemic review. *Journal of Cosmetic Dermatology*, 20(9), pp.2729-2738.
- Goldstein, B.G., Hong, A., Levy, M.L. and Alexis, A.F., 2022. Keloids and hypertrophic scars. *Delavalle R, Levy M, Alexis A. Corona R, editors. UpToDate.[Internet]. Waltham (MA). UpToDate Inc.*
- Hedayatyanfard, K., Haddadi, N.S., Ziai, S.A., Karim, H., Niazi, F., Steckelings, U.M., Habibi, B., Modarressi, A. and Dehpour, A.R., 2020. The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation. *Experimental Dermatology*, 29(9), pp.902-909.
- Hedayatyanfard, K., Ziai, S.A., Niazi, F., Habibi, I., Habibi, B. and Moravvej, H., 2018. Losartan ointment relieves hypertrophic scars and keloid: A pilot study. *Wound Repair and Regeneration*, 26(4), pp.340-343.
- Homer, N.A., Hanafy, M.S., Baer, S.C., Watson, A.H., Somogyi, M., Shore, J.W., Blaydon, S., Durairaj, V.D., Cui, Z. and Nakra, T., 2022. 5-Fluorouracil with microneedling modulates wound healing in a murine model: An immunohistochemical analysis of mechanism and dose efficacy. *Ophthalmic Plastic & Reconstructive Surgery*, 38(6), pp.596-601.

- Iannello, S., Milazzo, P., Bordonaro, F. and Belfiore, F., 2006. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid-two case reports and literature review. *Medscape General Medicine*, 8(4), p.60.
- Jian, K., Yang, C., Li, T., Wu, X., Shen, J., Wei, J., Yang, Z., Yuan, D., Zhao, M. and Shi, J., 2022. PDGF-BB-derived supramolecular hydrogel for promoting skin wound healing. *Journal of Nanobiotechnology*, 20(1), p.201.
- Jiang, Z.Y., Liao, X.C., Liu, M.Z., Fu, Z.H., Min, D.H., Yu, X.T. and Guo, G.H., 2020. Efficacy and safety of intralesional triamcinolone versus combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: A systematic review and meta-analysis. *Aesthetic Plastic Surgery*, 44(1), pp.1859-1868.
- Jin, J., Tang, T., Zhou, H., Hong, X.D., Fan, H., Zhang, X.D., Chen, Z.L., Ma, B., Zhu, S.H., Wang, G.Y. and Xia, Z.F., 2022. Synergistic effects of quercetin-modified silicone gel sheet in scar treatment. *Journal of Burn Care & Research*, 43(2), pp.445-452.
- Kommana, N., Bharti, K., Surekha, D.B., Thokala, S. and Mishra, B., 2020. Development, optimization and evaluation of losartan potassium loaded Self Emulsifying Drug Delivery System. *Journal of Drug Delivery Science and Technology*, 60(1), p.102026.
- Kumar, P.M. and Ghosh, A., 2017. Development and evaluation of silver sulfadiazine loaded microsphere based gel for partial thickness (second degree) burn wounds. *European Journal of Pharmaceutical Sciences*, 96(1), pp.243-254.
- Latoni, D.I., McDaniel, D.C., Tsao, H. and Tsao, S.S., 2024. Update on the pathogenesis of keloid formation. *The Journal of Investigative Dermatology Innovations*, p.100299.
- Lee, J. and Kim, J., 2020. Minimal-Invasive Technologies for Treatment of HTS and Keloids: Corticosteroids. *Textbook on Scar Management: State of the Art Management and Emerging Technologies*, pp.243-250.
- Limandjaja, G.C., Niessen, F.B., Scheper, R.J. and Gibbs, S., 2021. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars. *Experimental Dermatology*, 30(1), pp.146-161.
- Macarak, E.J., Wermuth, P.J., Rosenbloom, J. and Uitto, J., 2021. Keloid disorder: Fibroblast differentiation and gene expression profile in fibrotic skin diseases. *Experimental Dermatology*, 30(1), pp.132-145.
- Murakami, T. and Shigeki, S., 2024. Pharmacotherapy for keloids and hypertrophic scars. *International Journal of Molecular Sciences*, 25(9), p.4674.

- Murphy, A., LeVatte, T., Boudreau, C., Midgen, C., Gratzer, P., Marshall, J. and Bezuhly, M., 2019. Angiotensin II type I receptor blockade is associated with decreased cutaneous scar formation in a rat model. *Plastic and Reconstructive Surgery*, 144(5), pp.803e-813e.
- Ogawa, R., Akaishi, S., Kuribayashi, S. and Miyashita, T., 2016. Keloids and hypertrophic scars can now be cured completely: Recent progress in our understanding of the pathogenesis of keloids and hypertrophic scars and the most promising current therapeutic strategy. *Journal of Nippon Medical School*, 83(2), pp.46-53.
- Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI), 2024. *Panduan Praktik Klinis Bagi Dokter Spesialis Dermatologi, Venereologi, dan Estetika Indonesia*. Jakarta: PERDOSKI. ISBN 978-623-99603-2-2.
- Port, H., Bay-Jensen, A.C., He, Y., Karsdal, M.A., Gantzel, T., Thudium, C.S. and Holm Nielsen, S., 2022. A highly sensitive biomarker of type II collagen C-terminal pro-peptide associated with cartilage formation. *International Journal of Molecular Sciences*, 24(1), p.454.
- Quong, W.L., Kozai, Y. and Ogawa, R., 2017. A case of keloids complicated by Castleman's disease: Interleukin-6 as a keloid risk factor. *Plastic and Reconstructive Surgery Global Open*, 5(5), pp.1-5.
- Rittié, L., 2017. Method for picosirius red-polarization detection of collagen fibers in tissue sections. In *Fibrosis* (pp. 395-407). Humana Press, New York, NY.
- Robinson, M.R., Lee, S.S., Kim, H., Kim, S., Lutz, R.J., Galban, C., Bungay, P.M., Yuan, P., Wang, N.S., Kim, J. and Csaky, K.G., 2006. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. *Experimental Eye Research*, 82(3), pp.479-487.
- Salati, S.A., 2019. Keloids—an extensive review in the light of recent literature. *Journal of Pakistan Association of Dermatologists*, 29(2), pp.225-249.
- Seo, W.Y., Kim, J.H., Baek, D.S., Kim, S.J., Kang, S., Yang, W.S., Song, J.A., Lee, M.S., Kim, S. and Kim, Y.S., 2017. Production of recombinant human procollagen type I C-terminal propeptide and establishment of a sandwich ELISA for quantification. *Scientific reports*, 7(1), p.15946.
- Shaheen, A., 2017. Comprehensive review of keloid formation. *Clinical Research in Dermatology Open Access*, 4(5), pp.1-18.
- Shen, Z., Shao, J., Sun, J. and Xu, J., 2022. Exosomes released by melanocytes modulate fibroblasts to promote keloid formation: A pilot study. *Journal of Zhejiang University-SCIENCE B*, 23(8), pp.699-704.
- Shin, J.U., Kim, S.H., Kim, H., Noh, J.Y., Jin, S., Park, C.O., Lee, W.J., Lee, D.W., Lee, J.H. and Lee, K.H., 2016. TSLP is a potential initiator of collagen

- synthesis and an activator of CXCR4/SDF-1 axis in keloid pathogenesis. *Journal of Investigative Dermatology*, 136(2), pp.507-515.
- Sidhu, G. and Preuss, C.V., 2021. Triamcinolone. In *StatPearls [Internet]*. StatPearls Publishing.
- Simpson, K.L. and McClellan, K.J., 2000. Losartan. *Drugs & Aging*, 16(3), pp.227-250.
- Tripathi, S., Soni, K., Agrawal, P., Gour, V., Mondal, R. and Soni, V., 2020. Hypertrophic scars and keloids: A review and current treatment modalities. *Biomedical Dermatology*, 4(1), pp.1-11.
- Utsunomiya, A., Chino, T., Kasamatsu, H., Hasegawa, T., Utsunomiya, N., Luong, V.H., Matsushita, T., Sasaki, Y., Ogura, D., Niwa, S.I. and Oyama, N., 2022. The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF- $\beta$  signaling. *Arthritis Research & Therapy*, 24(1), p.94.
- Wang, R., Mao, Y., Zhang, Z., Li, Z., Chen, J. and Cen, Y., 2016. Role of verapamil in preventing and treating hypertrophic scars and keloids. *International Wound Journal*, 13(4), pp.461-468.
- Wang, Z.C., Zhao, W.Y., Cao, Y., Liu, Y.Q., Sun, Q., Shi, P., Cai, J.Q., Shen, X.Z. and Tan, W.Q., 2020. The roles of inflammation in keloid and hypertrophic scars. *Frontiers in Immunology*, 11(1), p.603187.
- Xu, J., Yang, E., Yu, N.Z., Wang, Y.B. and Long, X., 2017. The radiation therapy in keloids treatment: A comprehensive review of pathomechanism, damage mechanisms and cellular response. *Plastic and Aesthetic Research*, 4, pp.116-126.
- Zhang, J., Liu, N., Wu, X., Wu, P., Song, N. and Ma, J., 2021. Identification of differentially expressed circular RNAs in keloid and normal skin tissue by high-throughput sequencing. *Dermatologic Therapy*, 34(2), p.e14745.
- Zhou, B., Lin, X., Xia, L., Gao, Z., Di, M., Wu, X. and Wang, W., 2024. The inhibitory effect of type V transforming growth factor- $\beta$  receptor antagonist on the proliferation of keloid fibroblasts by suppressing insulin-like growth factor-binding protein 3-interleukin-6 signaling. *Dermatologica Sinica*, 42(4), pp.255-26.